Alzheimer Disease, Magnetic Resonance Spectroscopy, Memory Complaint, Phosphorylated Metabolism Profile
Conditions
Brief summary
Alzheimer disease is a frequent disease in the late ages that results in global alteration of cognitive functions. In which memory complaint can be isolated in the early stages. Physiopathology of neuronal degenerescence in Alzheimer disease is complex, two main histological lesions are known, amyloid plaques and neurofibrillar tangles. Beyond the histological knowledge, alterations of neuronal metabolism are described such as oxydative phosphorylation and glycolytic pathway. These metabolism alterations are involved in neuronal death. Multi-nucleus magnetic resonance spectroscopy is a non-invasive non-irradiant imagery technique already used in routine. This technic allows the phosphoenergetic pool assessment, that inform about cellular metabolism. The aim of the study is to explore the phosphorylated metabolism patterns as predictive biomarkers of cognitive decline in patients with a memory complaint diagnosed.
Interventions
OTHERAdditional sequence performed during MRI scan
An additional sequence will be performed during the MRI scan.
Sponsors
Poitiers University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 90 Years
Healthy volunteers
No
Inclusion criteria
1. Memory complaint, leading to a medical visit at the Centre Mémoire de Ressources et de Recherche (CMRR) of Poitiers, and for which an MRI is needed in routine exploration. 2. Age inferior at 90 years old 3. Mini Mental State Examination (MMSE) score between 20 and 30 4. Patient without guardianship measure, without restricted liberty. 5. Patient who benefits from social security
Exclusion criteria
1. Vascular, tumor, inflammatory pathology diagnosed by MRI 2. Other diagnosed neurodegenerative disease than Alzheimer disease 3. Other non neurodegenerative neurological disease 4. Vital risk at short term 5. Severe and uncontrolled psychiatric disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| phosphorylated metabolism profile assessment as predictor of cognitive decline in patients with memory complaint. | ONE YEAR | correlation between brain phosphorylated metabolism (Pcr, ATP, PME, PDE, cho, NAA, Cr, PH) at the inclusion and MMSE on 2 years. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Correlation between phosphorylated metabolite and final diagnostic of Alzheimer disease or not. | ONE YEAR | Correlation between brain metabolite (Pcr, ATP, PME, PDE, cho, NAA, Cr, PH) and Alzheimer disease final diagnostic. |
| Correlation between phosphoryled metabolite and variability of cerebro spinal fluid biomarkers | ONE YEAR | Correlation between brain metabolite (Pcr, ATP, PME, PDE, cho, NAA, Cr, PH) and cerebro spinal fluid biomarkers (B-amyloid Tau protein and Phosphorylated-Tau Protein) |
| Correlation between multinuclear magnetic resonance spectroscopy data and severity of cognitive dysfunction, at the inclusion and at one year. | ONE YEAR | Correlation between brain metabolite (Pcr, ATP, PME, PDE, cho, NAA, Cr, PH) and MMS score at the inclusion and at one year. |
| Evolution of multinuclear magnetic resonance spectroscopy data at one year and cognitive decline at one year. | ONE YEAR | Comparison at the inclusion and at one year of brain metabolite (Pcr, ATP, PME, PDE, cho, NAA, Cr, PH) and MMS score. |
Countries
France
Outcome results
None listed